Oct. 14 (Fri.) ,2016 10:00-11:30

Annex Hall

Simultaneous Interpretation

New Horizons of Immuno-oncology

As the beginning of the era with novel cancer immunotherapy of checkpoint targeting, the fully human cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking monoclonal antibody, ipilimumab, was approved by the US Food and Drug Administration (FDA) in 2011. In parallel with CTLA-4, programmed death 1 pathway (PD-1/PD-L1) blockades have shown the outstanding clinical efficacy in various types of cancer including lung, renal cell, stomach and ovary, and so on. These antibodies indicate broad and diverse opportunities to enhance antitumor immunity with the potential to produce durable clinical responses. Based on scientific evidences, cancer immunotherapy was elected as the breakthrough of 2013 in “Science”. A further progression is expected as the 4th generation cancer therapy follows the use of surgical treatment, radiotherapy and chemotherapy. In this seminar, lectures for the present and perspective in immune-oncology will be discussed by the outstanding specialists from academia and industrial researchers.


Ryuzo Ueda

Professor, Department of Tumor Immunology, Aichi Medical University School of Medicine

Novel Cancer Immunotherapy Targeting Regulatory T cells

Hiroyoshi Nishikawa

Director, Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center

Heterogeneity of Human Tumor Immune-microenvironment and Its Modulation

Yutaka Kawakami

Dean of Graduate School of Medicine, Professor, Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine

Engineered T Cell Therapy in Japan

Masanobu Kimura

General Manager, Project Management Department, Project Management Department, TAKARA BIO

Future of Checkpoint Inhibitors

Shinta Cheng

Asia-Pacific Immuno-Oncology Development Lead, Bristol-Myers Squibb

Close Window